Aryl and heteroaryl sulfonamides (ArSO 2 NH 2 ) are therapeutically used to inhibit the catalytic activity of carbonic anhydrases (CAs). Using a 'click-tail' approach a novel class of glycoconjugate benzene sulfonamides have been synthesized that contain diverse carbohydrate-triazole tails. These compounds were assessed for their ability to inhibit three human CA isozymes in vitro: cytosolic hCA I and hCA II, and transmembrane, tumourassociated hCA IX. This isozyme has a minimal expression in normal tissue but is overexpressed in hypoxic tumours and its inhibition is a current approach towards new cancer therapies. The qualitative structure-activity for all derivatives demonstrated that the stereochemical diversity present within the carbohydrate tails effectively interrogated the CA active site topology, to generate several inhibitors that were potent and selective towards hCA IX -an important outcome in the quest for potential cancer therapy applications based on CA inhibition. 2 3
Introduction
The carbonic anhydrase (CA, EC 4.2.1.1) family of Zn(II) metalloenzymes is ubiquitous to all eukaryotic and most prokaryotic cells. 1 This enzyme efficiently catalyses the hydration of carbon dioxide (CO 2 ) to give bicarbonate anion (HCO 3 -) and a proton (H + ), a regulatory reaction that underpins fundamental physiological processes associated with pH control, ion transport and fluid secretion. [2] [3] [4] For decades, inhibitors of CA have been a mainstay of human clinical intervention for a range of diseases, however more recently a role for CA inhibition as an anticancer therapy has been identified owing to the overexpression of some CA isoforms (CA IX and CA XII) in cancer cells and a minimal expression in normal tissue. The latter has further increased interest in this enzyme family as a therapeutic target. [5] [6] [7] The classical recognition fragment for small molecules to bind the active site of CA is an aromatic sulfonamide moiety -ArSO 2 NH 2 . [1] [2] [3] 8 The sulfonamide anion (ArSO 2 NH -) coordinates to the CA active site Zn(II) and so inhibits the catalytic ability of the enzyme. This aromatic sulfonamide group has served as a very reliable anchor upon which medicinal chemists have appended 'tails' to deliver inhibitors with improved potency and desirable selectivity profiles 7 reaction was found to be sluggish, even at elevated temperatures. However, when using 10 mol% of the Cu(I) source and 20 mol% of ascorbate, triazole formation proceeded smoothly in all cases and under very mild conditions. Reactions were generally complete following 30 min of vigorous stirring (as evidenced by TLC). The O-acetate groups of the amide series 2a-2g were subsequently removed using methanolic sodium methoxide to liberate the fully deprotected sugar analogues 2a'-2g' in quantitative or near quantitative yields. These basic reaction conditions proved unsuitable for the synthesis of the ester series 3a'-3g', owing to the methoxide anion participating also in transesterification, whereby cleaving the CA anchor from the sugar triazole tail. More conveniently, the azido sugar panel were first de-Oacetylated to give the deprotected azido sugars a'-g' (R = Ac -> R = H) which were then reacted with scaffold 3 to give the deprotected sugar ester series 3a'-3g'. All new compounds were characterized using 1D 1 H and 13 C NMR spectroscopy, 2D NMR spectroscopy (gCOSY, gHSQC, gHMBC as required), elemental analysis and HRMS.
Insert Scheme 2
Insert Figure 2 Carbonic Anhydrase Inhibition hCA I, II, and IX enzyme inhibition data (determined by assaying the CA catalyzed hydration of CO 2 ) 23 for 2, 3 and the 28 new glycoconjugate sulfonamides are presented in Table 1 . The selectivity ratios for inhibition of isozyme IX cf. I and II are also given in Insert Table 1 The parent amide scaffold 2 and ester scaffold 3 exhibited inhibition and isozyme selectivity similar to each other against the three hCA isozymes investigated. Compounds 2 and 3 had greatest efficacy at hCA II (K i s of 47 and 45 nM, respectively), approximately 2-fold weaker inhibition at hCA IX (113 and 104 nM, respectively) and an order of magnitude again weaker inhibition at hCA I (6100 and 4000 nM, respectively).
Isozyme hCA I. At hCA I the triazole linked carbohydrate moiety had minimal effect on inhibition, with 26 of the 28 compounds exhibiting affinity similarly (μM range) to the parent compounds 2 and 3. The two notable exceptions were compounds 3c' and 3e', both contained an ester linkage and a deprotected (free hydroxy) sugar. Compounds 3c' and 3e'
were 400 to 500-fold more potent than their parent ester scaffold 3 (K i s of 7.7 nM and 9.6 nM, respectively) and more potent than any of the standard sulfonamide inhibitors tested.
This result was extremely encouraging as it provided confirmation that the subtle structural differences in the sugar tail could indeed discriminate CA isozyme active site topology to substantially influence enzyme inhibition characteristics.
Isozyme hCA II. At hCA II the sugar triazole tail had a variable effect on CA inhibition -with some derivatives improved inhibition was observed while with others weaker inhibition was observed -when compared to the parent compounds 2 and 3. The ester linked deprotected sugars (3a'-3g') had tightly grouped K i s, ranging from 5. Derivatives 2d, 2e and 2f exhibited 6-, 50-and 36-fold higher inhibition, respectively, than their deprotected sugar counterparts, while derivatives 2a, 2b and 2c were each weaker hCA II inhibitors than their deprotected sugar counterparts. In summary, for the seven different glycosyl triazole tails studied, the four groupings of amide, ester, sugar-OAc or sugar-OH, did not behave in a consistent direction with respect to hCA II inhibition. This in vitro data will be important for understanding future in vivo data, as it is clear that the acetates could serves as prodrugs in the in vivo environment. 29 Similarly to the results for hCA I, these results again demonstrate that the sugar tails interrogate the enzyme active site with an intricacy of interactions that permit marked discrimination of enzyme inhibition. sugar-OAc derivatives (2x) were more potent than sugar-OH derivatives (2x') except for the glucuronic acid derivatives (2e' more potent than 2e), while in the ester series this trend was completely reversed, with sugar-OH derivatives (3x') more potent than sugar-OAc derivatives (3x), again with the exception of the glucuronic acid derivatives (3e more potent than 3e').
Compounds 2b, 3b', 3c', 2e', 3f', 3g and 3g' were all stronger inhibitors of hCA IX than the 
Conclusions
Selective inhibition among isozymes is often a challenging hurdle in the drug discovery process, however to maximise the benefits of any future therapies involving CA inhibition, it is essential to develop isozyme-specific compounds. Conservation of active site structure and topology within the CA enzyme family has made it difficult to target subtle isozyme differences by rational drug design. Here we have explored 'click-tailing' carbohydrates onto the ArSO 2 NH 2 CA pharmacophore as a drug solubilizing and isozyme differentiating strategy. This work presents a new class of CA inhibitors comprising triazole-tethered carbohydrate tails, the first of which to have been generated through 'click chemistry'. The qualitative structure-activity demonstrated that the stereochemical diversity within the carbohydrate tails effectively interrogated the CA active site topology, generating in some instances inhibitors with hCA IX selectivity -an important outcome in the quest for potential cancer therapy applications. Sugar tails may therefore prove a valuable approach to generate CA isozyme selective compounds. A powerful example is glucose (2a, 2a', 3a, 3a') and galactose (2b, 2b', 3b, 3b') epimer derivatives that have drastically different inhibition and selectivity profiles yet the sole stereochemical difference is over 14 atoms removed from the sulfonamide moiety. The relative ease of synthetic access to azido sugars coupled with the venerability of the cycloaddition reaction has provided an efficient route to the carbohydratebased CA inhibitors. We intend to more fully explore this "click tailing' strategy for the development of CA inhibitors for therapeutic investigation. 
N-(Prop-2-ynyl)-4-sulfamoylbenzamide (2).
To a stirring solution of 1 (2.0 g, 9.9 mmol) and propargyl amine (0.64 mL, 9.9 mmol, 1.0 equiv) in dry DMF (40 mL) was successively added N-hydroxybenzotriazole monohydrate (0.94 g, 6.6 mmol, 0.6 equiv), diisopropylethylamine (1.7 mL, 9.9 mmol, 1.0 equiv) and HBTU (3.8 g, 9.9 mmol, 1.0 equiv).
The deep yellow solution was stirred at room temperature under nitrogen for 1 hour when found complete by TLC. The mixture was concentrated under reduced pressure and ethyl acetate (40 mL) was added. The organic extract was washed with water (40 mL) and back extracted with ethyl acetate (3 x 40 mL). The organic extracts were combined, and washed with brine (50 mL). Neutralization of the solution by Amberlite IR-120 ion exchange resin, followed by filtration and evaporation of the filtrate to dryness afforded pure material by NMR. Likewise, the analogous esters 3a' -g' were prepared by deprotecting the peracetylated glycosyl azides af or the 6-deoxy-6-azido glucoside g in the same way as described above, prior to the cycloaddition reaction with 3 (see scheme 2). used for determining the initial velocity. The uncatalyzed rates were determined in the same manner and subtracted from the total observed rates. Stock solutions of inhibitor (1 mM) were prepared in distilled-deionized water with 10-20% (v/v) DMSO (which is not inhibitory at these concentrations) and dilutions up to 0.01 nM were done thereafter with distilleddeionized water. Inhibitor and enzyme solutions were preincubated together for 15 min at room temperature prior to assay, in order to allow for the formation of the E-I complex. The inhibition constants were obtained by non-linear least-squares methods using PRISM 3. The curve-fitting algorithm allowed us to obtain the IC50 values, working at the lowest concentration of substrate of 1.7 mM), from which K i values were calculated by using the Cheng-Prusoff equation. [24] [25] [26] [27] [28] The catalytic activity (in the absence of inhibitors) of these enzymes was calculated from Lineweaver-Burk plots, as reported earlier, and represent the mean from at least three different determinations. [24] [25] [26] [27] [28] Enzyme concentrations in the assay system were: 9.2 nM for hCA I, 7.3 nM for hCA II and 8.5 nM for hCA IX. Enzymes used here were recombinant ones, prepared and purified as described earlier. 
4-({[4-(Aminosulfonyl)benzoyl]amino}methyl-1-(2',3',4',6'-tetra-O-acetyl-β-Dglucopyranosyl)-1-H-1,2,3-triazole (2a

4-({[4-(Aminosulfonyl)benzoyl]amino}methyl-1-(β-D-glucopyranosyl)-1-H-1,2,3-triazole (2a').
4-({[4-(Aminosulfonyl)benzoyl]amino}methyl-1-(2',3',4',6'-tetra-O-acetyl-β-Dgalactopyranosyl)-1-H-1,2,3-triazole (2b
4-(4-Sulfamoylbenzamido)methyl-1-(β-D-galactopyranosyl)-1-H-1,2,3-triazole (2b'
4-({[4-(Aminosulfonyl)benzoyl]amino}methyl-1-(β-D-garabinopyranosyl)-1-H-1,2,3-triazole (2c').
4-({[4-(Aminosulfonyl
